SCHEMBL3443894

SCHEMBL3443894

Cc1ccc2c(c1)c1cc(-c3cccnc3)c(=O)n(C)c1n2C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 2/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ CYP11B2 P19099 2/20 0.42
▸ MAP2K4 P45985 1/20 0.42
▸ MAPK14 Q16539 1/20 0.41
▸ NR4A2 P43354 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ APAF1 O14727 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ KCNA3 P22001 2/20 0.40
▸ EGLN1 Q9GZT9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3443882 0.85 KDM4E (0.43) MAPK14KDM4EAPAF1MAPTPKM
SCHEMBL3867984 0.85 HSD17B10 (0.46) KDM4EAPAF1MAPTPKMIDO1
Hydrochloric Acid SCHEMBL3444526 0.84 KDM4E (0.42) MAPK14KDM4EAPAF1MAPTPKM
SCHEMBL2385054 0.81 MAPT (0.46) MAPK14KDM4EAPAF1MAPTPKM
SCHEMBL2382248 0.80 MAPT (0.43) MAOBMAP2K4KDM4EAPAF1MAPT
SCHEMBL2386185 0.80 MAOB (0.43) MAOBMAPK14KDM4EAPAF1MAPT
SCHEMBL3867457 0.78 KDM4E (0.41) CYP2A6NR4A2KDM4EAPAF1MAPT
SCHEMBL2385267 0.78 KDM4E (0.43) KDM4EAPAF1MAPTPKMIDO1
SCHEMBL3446228 0.77 BRD4 (0.45) MAPK14KDM4EAPAF1MAPTPKM
SCHEMBL3445171 0.77 MAP2K4 (0.49) CYP2A6MAOAMAOBCYP11B2MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816368-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2010-10-19 — — US claimed
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2009-02-12 — — US claimed
US-7456193-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-11-25 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics PNPO, DPYD, PDXK CYP2A6 318/4885MAOA 266/4885MAOB 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback